Previous 10 | Next 10 |
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., Pres...
2023-12-24 13:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at 1:50 p.m. ET. The fireside chat will be webcast live ...
2023-11-06 02:05:59 ET Summary Relay Therapeutics has maintained clinical momentum in its Phase 1/2 ReFocus trial for RLY-4008, showing promise for FGFR2-altered cholangiocarcinoma. The company's financial health is strong, with ample short-term liquidity and significant assets co...
Relay Therapeutics Inc. (RLAY) is expected to report $-0.83 for Q3 2023
2023-11-03 01:07:35 ET More on Relay Therapeutics Relay Therapeutics surges 13% on early-stage data on tumors asset Seeking Alpha’s Quant Rating on Relay Therapeutics For further details see: Relay Therapeutics GAAP EPS of -$0.54, revenue of $25.2M
Reported initial RLY-4008 (lirafugratinib) data demonstrating durable responses across multiple FGFR2-altered solid tumors Announced plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet combinations in HR+/HER2- breast cancer by YE 2023 Updated pipeline to extend cash runwa...
CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2023 financial resu...
2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
2023-10-12 19:15:54 ET More on Relay Therapeutics Relay Therapeutics: Market May Be Prematurely Dismissing RLY-2608 Seeking Alpha’s Quant Rating on Relay Therapeutics Historical earnings data for Relay Therapeutics Financial information for Relay Thera...
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transform...
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that the company will host a N...
2024-05-10 16:30:03 ET Oppenheimer analyst issues MARKET OUTPERFORM recommendation for RLAY on May 10, 2024 02:00PM ET. The previous analyst recommendation was Market Outperform. RLAY was trading at $6.425 at issue of the analyst recommendation. The overall analyst conse...